The planned restriction of PFAS poses major challenges for medical technology in particular. Over 100 experts discussed risks, alternatives and regulatory developments on March 26, 2025 in St. Gallen.

Perfluorinated and polyfluorinated alkyl compounds (PFAS) are indispensable in many high-tech products – especially in medical technology, such as stents, grafts and endoscopes. The new regulatory plans of the European Chemicals Agency (ECHA) are forcing companies to rethink. At the workshop in St. Gallen, both the regulatory background and specific solutions were discussed in depth. A risk-based, step-by-step replacement of fluorine-containing substances was identified as a promising approach. The aim is to combine ecological responsibility with patient safety.

A particular focus was placed on the ongoing ECHA procedure. Participants were given an overview of deadlines, processes and the opportunity to contribute their own data as part of the socio-economic assessment. At the same time, it became clear that there is no standard solution for replacing PFAS. Rather, individual material decisions are required – depending on the respective application.

Material alternatives, detection methods and international perspectives

A practical five-stage model for evaluating PFAS-free materials was presented. It helps companies to include both acute hazards and long-term effects in their decision-making. The analysis of fluorine-containing compounds was also discussed – current detection methods often reach their limits in terms of accuracy and effort. Improved methods are therefore essential. A final look at the USA showed that several states already have specific PFAS restrictions in place. It is therefore crucial for internationally active companies to keep an eye on regulatory developments worldwide. The workshop made it clear that the path to PFAS alternatives can only succeed through close cooperation between industry, research and authorities.